Enveric Biosciences, Inc. · NASDAQ:ENVB
Enveric Biosciences — Investor Presentation (October 2021)
26 slides from Enveric Biosciences's investor presentation, Oct 5, 2021
Slide 1: Enveric Biosciences Investor Deck October 2021
ENVERIC © tmornecine Mental Health™ OSC ENCES Investor Deck October 2021 NASDAQ: ENVB
Slide 2: No Offer or Solicitation
No Offer or Solicitation This communication is for informational purposes only and isnot intended to and does not constitute an offer to sell, or the slictation ofan offer to buy any securities ora solicitation of any vote or approval. It does nt constitute a prospectus or prospectus equivalent docu
Slide 3: A platform of next generation psychedelic and cannabinoid medicines
A platform of next generation psychedelic and cannabinoid medicines We leverage our discovery engine and intellectual property portfolio to create next-generation psychedelics and cannabinoids for the mind and body, with lead products in Cancer. IVAN SON NS WH Wh Vi “] i: A ‘ ZB VW LLL), Leg LEA Oe
Slide 4: Management Team
Management Team Dr. Joseph Tucker Chief Executive Officer & Director Dr. Tucker has 20 years experience in biotechnology, founded and took public 3 biotech companies as well as sold company to Trilum Therapeutics. Dr. Bob Wilkins Chief Medical Officer Former Medical Director at Abbott Laboratories,
Slide 5: World Class Advisors — Research and Clinical
World Class Advisors — Research and Clinical Michael J. Zelefsky, M.D. Chairman Dr. Michael Zelefsky is a board-certified radiation oncologist and co-leader of Memorial Sloan Kettering's Genitourinary Disease Management Team —a multidisciplinary group of physicians who work together to treat patient
Slide 6: Enveric Bio: A Compelling Investment Thesis
Enveric Bio: A Compelling Investment Thesis Powerful IP portfolio - 14 Patents filed Multi-billion-dollar opportunities with large patient populations in mind and body Psybrary contains 1M+ molecules encompassing Gen2 and Gen3, including non- hallucinogenics PsyAI allows us allows us to target indic
Slide 7: Execute on Clinical Assets and Invest in Discovery Assets
Execute on Clinical Assets and Invest in Discovery Assets Indication Evi0i* GBM Evi02 RD EVM201 CRD EVM202 PTSD a * Evaluating strategic alternatives Discovery Preclinical Phase 1 a Phase 2 Phase 3 Major Next Steps Phase 1 IND Submission Preclinical Preclinical Timing Qt 2022 Q2 2022 Qt 2022 Q3 2022
Slide 8: The Platform — Next Generation Medicines
The Platform — Next Generation Medicines MIND Psychedelics MIND $70+ BILLION PSYBRARY™ Hallucinogenic * Non-Hallucinogenic Cancer Related Distress $20+Bt Depression $12+ B: PTSD f $990+ M3 Anxiety $7* Bt Substance Abuse $314 BS BODY $140+ BILLION BODY cannabinoids Non-Hallucinogenic Radiodermatitis
Slide 9: Initial Focus: Cancer Related Distress (CRD) and Radiodermatitis (RD)
Initial Focus: Cancer Related Distress (CRD) and Radiodermatitis (RD) Cancer Related Distress Radiodermatitis 50% of cancer patients go through Radiation 5 ; 71% of cancer patients report mental health treatment challenges* 90% of those patients experience Estimated market size of 12-13MM people Rad
Slide 10: Psychedelics – Addressing the Mind
Slide 11: Psychedelics: Market and Investor Validation
Psychedelics: Market and Investor Validation Market Validation e J8&J Spravato first e FDA Breakthrough ¢ Bio-pharma and Life Science approved Psychedelic Status for 2 Drugs Institutional Investors are putting money to work in a © $3B Estimated Peak ° MDMA meaningful way in be ae Psychedelics Sprava
Slide 12: Psychedelics — Treatments for today and tomorrow
Psychedelics — Treatments for today and tomorrow Optimized NCE for Improved Outcomes Chemically Modified into Prodrugs Classic Psychedelics
Slide 13: Psybrary allows us to potentially expand market exponentially
Psybrary allows us to potentially expand market exponentially Current Therapist-delivery model limits the Patient Population Served Gen1&2 Psychedelic Model Psychotherapy with Psychedelics <MR TraditionavRK Self-AdminModél.at Home
Slide 14: Discovery Team + World-class Laboratories
Discovery Team + World-class Laboratories
Slide 15: Psybrary — Engine for Next Generation Molecules
Psybrary — Engine for Next Generation Molecules Synthetic pene en een ene Biology Serre eee ’ Engineered Microbes ‘ Biocatalysis - Enzymes ~G-O©-G Feed substrate Enzyme catalyzes reaction to change New product molecules to enzyme non-natural substrate into new are released by the product molecules e
Slide 16: Psybrary offers Massive Diversity Enabling Generation & Drugs
Psybrary offers Massive Diversity Enabling Generation 2 & 3 Drugs c Broad Intellectual Property Coverage Derivative Molecules Protected J : ae ll 10 Filed Patents 1 Million+ * K N rT iled Pateni Mescaline/ i 1 Million+ MDMA 4 Filed Patents | Classic Molecule Patent Filings 5-HT2a (1) These figures r
Slide 17: PsyAI™ — Organizing and Analyzing the vast Psybrary
PsyAI™ — Organizing and Analyzing the vast Psybrary 4 ° a © £ o = Prediction
Slide 18: Psychedelic Development Pipeline
Psychedelic Development Pipeline EVM201 (CRD Gen2): EVM301 (CRD Gen3): e Current: Hit to Lead © Current: Target Identification {6} e Next Step: Lead Optimization © Next Step: Assay Development Se EVM202 (PTSD Gen2): EVM302 (PTSD Gen3): a © Current: Hit Discovery © Current: Target Identification O0O0
Slide 19: Industry Landscape: Rapidly Evolving Sector
Industry Landscape: Rapidly Evolving Sector Company DemeRx Compass MindMed MindMed Cybin Seelos Maps GH Research Type NASDAQ: ATAL NASDAQ: CMPS NASDAQ: MNMD. NASDAQ: MNMD. NYSE/NEO: CYBN OTCQB: CLXPF NASDAQ: SEEL Non-profit GHRS Indication Opioid Use Disorder Treatment Resistant Depression Multiple
Slide 20: Cannabinoids – Addressing the Body
Slide 21: Human Endocannabinoid System Discovered in the 90s
Human Endocannabinoid System Discovered in the 90s Cannabinoids Tap Into Natural Mechanisms Of Human Body “In the 1990’s, scientists discovered endocannabinoids, the natural cannabis-like molecules produced by the human body. Scientists began to realize cannabis exerted its effects, in part, by mimi
Slide 22: Cannabis & Inflammation
Cannabis & Inflammation UNIVERSITY ae HARVARD 1; @ THE UNIVERSITY & MEDICAL SCHOOL - OFLONDON! Kentucky. aneeseianee of EDINBURGH 7 CALGARY . UNIMORE Stanford Wan ATE 2 Medicine at (2 GL University G UNIVERSITA Mount Massachusetts oO SIENA Sinai am : The University of > UNIVERSITY DALHOUSIE WHS] = M
Slide 23: Radiation Dermatitis (RD): $1B Opportunity to Improve High Unmet Need
Radiation Dermatitis(RD): $1B Opportunity to Improve High Unmet Need Current Problem Scientific Hypothesis Enveric Solution Path Enveric novel formulation for RD IND Filing Q2 2022 Protocol & Site PI Finalized Phase 1/2 Study Targeted Q3 2022 Higher Probability Clinical Pathway * 50% cancer patients
Slide 24: First Nationally Listed Psychedelic and Cannabinoid Biotech Company
jl Nasdaq :ENve First Nationally Listed Psychedelic and Cannabinoid Biotech Company Cash and Cash equivalents as of June 30‘, 2021 e Cash On-hand - $20.6MM © Debt - Zero e@ Jan 2021: $9.5 million e Feb 2021: $12.1 million e Warrant exercise (Mar 2021): $3.3 million © Outstanding shares: 31.3 million
Slide 25: Expected Catalysts and Milestones
Expected Catalysts and Milestones PsyAI-powered completion of Early Drug Discovery in Q4 2021 EV101: GBM First Patient in Q1 2022 EV102: RD IND in Q2 2022 EV102: RD First Patient in Q3 2022 EVM201: Initiate preclinical studies in Q1 2022 Add 7 Patents to Portfolio by Q3 2022
Slide 26: Building a Discovery & Clinical Platform to Serve the Mind and Body
BUILDING A DISCOVERY & CLINICAL PLATFORM TO SERVE THE MIND AND BODY INVESTOR PRESENTATION (NASDAQ: ENVB) For more information please contact: ir@enveric.com
Enveric Biosciences — Investor Presentation (October 2021) on 6ix